| Abbreviation | Full name |
| ADA | Adenosine Deaminase Deficiency |
| ADC | Antibody–Drug Conjugate |
| ANDA | Abbreviated New Drug Application |
| BLA | Biologics License Application |
| BPCIA | Biologics Price Competition and Innovation Act |
| CBER | Center for Biologics Evaluation and Research |
| CDE | Center for Drug Evaluation |
| CDER | Center for Drug Evaluation and Research |
| CFDA | China Food and Drug Administration |
| COPD | Chronic Obstructive Pulmonary Disease |
| CTA | Clinical Trials Application |
| DO | Drug Organization (Japan) |
| DRG | Diagnosis‐Related Groups |
| EGRF | Endothelial Growth Factor Receptor |
| EMA | European Medicines Agency |
| EU | European Union |
| FDA | Food and Drug Administration |
| GCP | Good Clinical Practice |
| GLP | Good Laboratory Practice |
| GMP | Good Manufacturing Practice |
| HER‐2 | Human Epidermal Growth Factor Receptor‐2 |
| IDL | Import Drug License (China) |
| IL‐5 | Interleukin‐5 |
| IMS | Intercontinental Medical Statistics |
| IV | Intravenous |
| JAAME | Japanese Association for the Advancement of Medical Equipment |
| KIKO | Another Name for OPSR (Japan) |
| LLP | Lipoprotein Lipase Deficiency |
| mABs | Monoclonal Antibodies |
| MHLW | Ministry of Health, Labour and Welfare (Japan) |
| MIDAS | Market Information on Global Sales Activities (from IQVIA) |
| NASDAQ (Index) | National Association of Securities Dealers Automated Quotations (Index) |
| NOBs | Non‐Original Biologics |
| OPSR | Organization for Pharmaceutical Safety and Research |
| PCSK‐9 | Proprotein Convertase Subtilisin/Kexin type 9 |
| PMDA | Pharmaceuticals and Medical Devices Agency (Japan) |
| PMDEC | The Pharmaceuticals and Medical Devices Evaluation Center |
| R&D | Research and Development |
| SC | Subcutaneous |
| SCID | Severe‐Combined Immuno‐Deficiency |
| TGA | Therapeutic Goods Administration |
| TNF | Tumor Necrosis Factor |
| WHO | World Health Organization |
